Fundraising Fox
🦊/Companies
Sign in

Genespire

4 known investors

Find your way into Genespire

353 people in our graph share verified history with the Genespire team — schools, employers, funds. One of them is your warm intro.

Jared Kesselheim, M.D.unlockedknows Lucia Faccio · together at Harvard Medical School (overlapped)
×7knows the team · via SDA Bocconi
×2knows the team · via Harvard Medical School
×2knows the team · via Università degli Studi di Padova

Genespire is a life sciences company backed by multiple venture capital investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners. Based on the investor page content, the company operates in the biotech and life sciences sector.

BiotechDeep TechDigital HealthHealthtech

Founders & leadership

DLDr. Lucia Faccio
Dr. Lucia FaccioinChief Executive OfficerDr. Lucia Faccio holds a degree in pharmaceutical chemistry from the University of Padua and a PhD in biotechnology from the University of L'Aquila in association with Harvard Medical School. She has over 20 years of experience in life science business development, including roles as Director of Research & Development at Fondazione Telethon since 2012, Partner at Sofinnova Partners starting in 2018, and Director of the Office of Biotechnology Transfer at San Raffaele Hospital, and is now CEO of Genespire.
DJDr. Julianne Smith
Dr. Julianne SmithChief Development Officer
DSDr. Simon Hawkins
Dr. Simon HawkinsVP Clinical Development
DSDr. Smaragda Angelidou
Dr. Smaragda AngelidouResponsabile CMC
DMDr. Mary Wang
Dr. Mary WangPatient Engagement Director
EBEmanuela Balzo
Emanuela BalzoinVP of FinanceEmanuela Balzo is VP Finance at Genespire, a pre-clinical gene therapy company, where she oversees financial governance and capital planning. She brings over 20 years of finance leadership across pharma and life sciences, including 12 years as Finance & Business Operations Director at Lundbeck Italia, and holds an MBA from SDA Bocconi and is a Chartered Accountant.
DSDr. Simona La Seta Catamancio
Dr. Simona La Seta CatamancioHead of Project Management
DA
Dr. Albert Molina GilAssociate Director CMC

Investors · 4

CDP Venture Capital✓ verifiedRome
Indaco Venture Partners✓ verifiedMilan
Sofinnova Partners✓ verifiedParis · $540K – $27M
XGEN Venture✓ verifiedMilan

Funding

SEC filings, press & company announcements

$52M disclosed across 1 of 2 rounds · 2020–2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Genespire Raises €46.6M in Series B Fundingfinsmes.com · Sep 2024Genespire raises $52m in Series B to trial paediatric gene therapypharmaceutical-technology.com · Sep 2024Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinicglobenewswire.com · Sep 2024Genespire raises US$52m in Series B round - European Biotechnology Magazineeuropean-biotechnology.com · Sep 2024News - Genespiregenespire.com · Jul 2020Genespire Raises €16M in Series A Financing - FinSMEsfinsmes.com · Apr 2020

Frequently asked questions

What does Genespire do?
Genespire is a life sciences company backed by multiple venture capital investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners. Based on the investor page content, the company operates in the biotech and life sciences sector.
Who are Genespire's investors?
Genespire's investors include CDP Venture Capital, Indaco Venture Partners, Sofinnova Partners, XGEN Venture.
How much funding has Genespire raised?
Genespire has disclosed $52M raised across 1 of its 2 known rounds.